NCT00781261View on ClinicalTrials.gov

Osteonecrosis of the Hip and Bisphosphonate Treatment

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Osteonecrosis
Interventions
DRUG

Zoledronic Acid

Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.

DRUG

Placebo

Subjects in the control group will receive a placebo drug for a similar period

Trial Locations (5)

2065

RECRUITING

Royal North Shore Hospital, Department of Rheumatology, Sydney

3144

RECRUITING

Cabrini Hospital, Melbourne

4029

RECRUITING

Royal Brisbane and Womens Hospital, Herston

4102

RECRUITING

Princess Alexandra Hospital, Brisbane

5011

RECRUITING

The Queen Elizabeth Hospital, Adelaide

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Sydney

OTHER

NCT00781261 - Osteonecrosis of the Hip and Bisphosphonate Treatment | Biotech Hunter | Biotech Hunter